Assessment of initial vancomycin dosing in neonates

Area of Science:

• Neonatal pharmacology
• Infectious disease management
• Pharmacokinetics

Background:

• Vancomycin is a recommended treatment for late-onset sepsis caused by coagulase-negative Staphylococcus in neonates.
• Current empirical dosing may not consistently achieve therapeutic vancomycin trough levels.

Purpose of the Study:

• To evaluate the effectiveness of an existing empirical vancomycin dosing regimen in neonates.
• To revise the vancomycin dosing regimen to improve target trough level achievement.

Main Methods:

• Collected data on vancomycin doses and serum levels in neonates.
• Calculated pharmacokinetic parameters to assess drug exposure.
• Determined the percentage of neonates achieving target trough levels (<10, 10-20, >20 mg/L).

Main Results:

• Only 34.2% of neonates achieved target vancomycin trough levels (10-20 mg/L) with the initial empirical regimen.
• Analysis indicated a need to increase empirical vancomycin doses across all neonatal age groups.
• The revised regimen (20-40 mg/kg/day) was predicted to achieve target levels in 72% of infants.

Conclusions:

• The initial vancomycin dosing regimen was inadequate for achieving target trough levels in neonates.
• A modified empirical vancomycin regimen is proposed to enhance therapeutic drug levels.
• Further clinical validation of the revised regimen in an independent cohort is necessary.